JRT (drug)

JRT
Above: JRT molecular structure Below: 3D representation of a (+)-JRT molecule
Clinical data
Drug classSerotonin receptor modulator; Serotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen; Psychoplastogen
ATC code
  • None
Identifiers
  • (7S)-N,N-diethyl-6-methyl-6,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),2,10,12(16),13-pentaene-4-carboxamide
PubChem CID
Chemical and physical data
FormulaC20H25N3O
Molar mass323.440 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)C1CN([C@@H]2CN3C=CC4=C3C(=CC=C4)C2=C1)C
  • InChI=1S/C20H25N3O/c1-4-22(5-2)20(24)15-11-17-16-8-6-7-14-9-10-23(19(14)16)13-18(17)21(3)12-15/h6-11,15,18H,4-5,12-13H2,1-3H3/t15?,18-/m1/s1
  • Key:ZYTVEPYZRGXVRK-KPMSDPLLSA-N

JRT is a serotonin receptor modulator and putative serotonergic psychedelic and psychoplastogen related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the embedded tryptamine structure within the ergoline ring system of LSD has been replaced with an isotryptamine structure.

It acts as a non-selective serotonin receptor modulator, including as a partial agonist of the serotonin 5-HT2A receptor and as an agonist or antagonist of various other serotonin receptors. The drug has psychedelic-like, psychoplastogenic, antipsychotic-like, antidepressant-like, and pro-cognitive effects in animals and preclinical studies, whilst lacking apparent pro-psychotic-like effects. It has significant but reduced psychedelic-like effects compared to LSD.

JRT was first described in the scientific literature by 2022. It was developed by David E. Olson and colleagues in association with Delix Therapeutics. The drug is being investigated as a possible treatment for schizophrenia.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.